Correlation Between Petroleo Brasileiro and Medtech Acquisition

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Petroleo Brasileiro and Medtech Acquisition at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Petroleo Brasileiro and Medtech Acquisition into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Petroleo Brasileiro Petrobras and Medtech Acquisition Corp, you can compare the effects of market volatilities on Petroleo Brasileiro and Medtech Acquisition and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Petroleo Brasileiro with a short position of Medtech Acquisition. Check out your portfolio center. Please also check ongoing floating volatility patterns of Petroleo Brasileiro and Medtech Acquisition.

Diversification Opportunities for Petroleo Brasileiro and Medtech Acquisition

0.22
  Correlation Coefficient

Modest diversification

The 3 months correlation between Petroleo and Medtech is 0.22. Overlapping area represents the amount of risk that can be diversified away by holding Petroleo Brasileiro Petrobras and Medtech Acquisition Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medtech Acquisition Corp and Petroleo Brasileiro is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Petroleo Brasileiro Petrobras are associated (or correlated) with Medtech Acquisition. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medtech Acquisition Corp has no effect on the direction of Petroleo Brasileiro i.e., Petroleo Brasileiro and Medtech Acquisition go up and down completely randomly.

Pair Corralation between Petroleo Brasileiro and Medtech Acquisition

Considering the 90-day investment horizon Petroleo Brasileiro Petrobras is expected to generate 5.1 times more return on investment than Medtech Acquisition. However, Petroleo Brasileiro is 5.1 times more volatile than Medtech Acquisition Corp. It trades about 0.08 of its potential returns per unit of risk. Medtech Acquisition Corp is currently generating about -0.04 per unit of risk. If you would invest  656.00  in Petroleo Brasileiro Petrobras on September 25, 2024 and sell it today you would earn a total of  637.00  from holding Petroleo Brasileiro Petrobras or generate 97.1% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy27.62%
ValuesDaily Returns

Petroleo Brasileiro Petrobras  vs.  Medtech Acquisition Corp

 Performance 
       Timeline  
Petroleo Brasileiro 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Petroleo Brasileiro Petrobras has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest conflicting performance, the Stock's fundamental drivers remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors.
Medtech Acquisition Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Medtech Acquisition Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Medtech Acquisition is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Petroleo Brasileiro and Medtech Acquisition Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Petroleo Brasileiro and Medtech Acquisition

The main advantage of trading using opposite Petroleo Brasileiro and Medtech Acquisition positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Petroleo Brasileiro position performs unexpectedly, Medtech Acquisition can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medtech Acquisition will offset losses from the drop in Medtech Acquisition's long position.
The idea behind Petroleo Brasileiro Petrobras and Medtech Acquisition Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Complementary Tools

Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance